3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Neoplasms
5
Multiple Myeloma
3
Hematologic Neoplasms
3
Thyroid Cancer, Papillary
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasm Metastasis
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Thyroid Carcinoma, Anaplastic
1
Rare Tumor
1
Ovarian Neoplasms
1
Lymphoproliferative Disorders
1
Leukemia, Hairy Cell
1
Laryngeal Neoplasms
1
Glioma
1
Erdheim-Chester Disease
1
Colorectal Cancer Metastatic
1
Adenocarcinoma, Follicular
1
Interventions
Magnetic Resonance Spectroscopy
10
Specimen Handling
9
Cisplatin
7
pembrolizumab
4
Radiation
4
Platinum
4
Biopsy
4
1,2-diaminocyclohexaneplatinum II citrate
4
Surgical Procedures, Operative
3
Radiotherapy, Intensity-Modulated
3
Radiotherapy
3
Cetuximab
3
toripalimab
2
cemiplimab
2
Interviews as Topic
2
Docetaxel
2
Chemoradiotherapy
2
Carboplatin
2
sacituzumab govitecan
1
merphos
1
ipatasertib
1
cobimetinib
1
cabozantinib
1
X-Rays
1
Vemurafenib
1
Tretinoin
1
Transurethral Resection of Bladder
1
Taxes
1
Surveys and Questionnaires
1
Standard of Care
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Laryngeal Neoplasms
×
Vemurafenib
×
Clear all
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled